“…Amphotericin B has been clinically used since 1957 (Walker & Walker, 1988), at first in the treatment of fungal infections. The majority of bioanalytical assays of amphotericin B in various matrices used for human PK studies were detected using conventional UV detection (Alak et al, 1996; Ayestarán et al, 1996; Bach, 1984; Baley et al, 1990; Barco et al, 2017; Bekersky et al, 2002a; Benson & Nahata, 1989; Brassinne et al, 1987; Chabot et al, 1989; Ching et al, 1983; Cleary et al, 1997; Collette et al, 1989, 1991; Demartini et al, 2005; Egger et al, 2001; Eldem & Arican‐Cellat, 2001; Eldem et al, 2001; Ganière Monteil et al, 1998; Golas et al, 1983; Heinemann et al, 1997; Hong et al, 2007; Hope et al, 2012; Hosotsubo et al, 1988; Hideo Hosotsubo & Hosotsubo, 1989; Hülsewede & Dermoumi, 1994; Husain et al, 2010; Kobayashi et al, 1987; Koren et al, 1988; Leclercq et al, 1985; Liu et al, 1995; Lopez et al, 1998; Lopez‐Galera et al, 1995; Mayhew et al, 1983; Nath et al, 1999; Ng et al, 1996; Nilsson‐Ehle et al, 1977; Persat et al, 2009; Shihabi et al, 1988; Vogelsinger, 2006; Walsh et al, 1998; Watanabe et al, 2010; Welte et al, 2015), which was more prominent before MS detection was standardized (Al‐Quadeib et al, 2014; Bekersky et al, 2002a; Deshpande et al, 2010; Hong et al, 2007; Husain et al, 2010; Lee et al, 2001; Qin et al, 2012; Qu et al, 2017; Roseboom, Thijssen, Rosing, Alves, Sundar, et al, 2022; Schuster et al,…”